From this cohort, we focused on 10 CRC patients treated with anti‐PD‐1 monotherapy. Notably, PRDX1 expression was significantly upregulated in ICI‐resistant patients without a pathological complete response (non‐pCR; n = 3) compared to ICI‐sensitive patients with a pathological complete response (pCR; n = 7) (Figure 1D). Here, PRDX1 is linked to colorectal carcinoma.